Presented at #AHA25: In a phase 1 trial, single-dose CRISPR-Cas9 gene editing targeting ANGPTL3 led to reductions in ANGPTL3 protein levels, with few adverse events. Full trial results: nej.md/43doGvu AHA Science

🔥It takes domain expertise to navigate a field and assess progress. Building (mediocre) AI models is easy—the challenge is rigorous evals. Beware of new benchmarks that are half baked or exclusion of SOTA to make performance seem impressive. THIS IS A PERVASIVE ISSUE IN AI x BIO

Our newly developed ChIP-CryoEM technique has, for the first time, visualized the moment when the UV-DDB protein recognizes and repairs UV-induced DNA damage within cells. nature.com/articles/s4146… #cryo #structure #biology

“How large language models encode theory-of-mind: a study on sparse parameter patterns” by Zhaozhuo Xu et al. npj Artificial Intelligence nature.com/articles/s4438…

Impaired cAMP–PKA–CREB1 signalling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia | Nature Metabolism nature.com/articles/s4225…

If you are excited about this idea and on the look out for a postdoc, this is your opportunity: chalmers.se/en/about-chalm…

Prometheus' co-CEO/co-founder is Vik Bajaj, most recently the CEO of Foresite Labs, where he helped co-found Xaira Therapeutics among other biotech efforts Cade Metz has the scoop on Bezos' new startup with $6.2bn in funding: nytimes.com/2025/11/17/tec…

Echocardiography is one of the hardest imaging tasks in medicine. A new Nature paper introduces EchoPrime, a multi view vision language AI trained on 12M echo video report pairs that outperforms all prior models across 23 benchmarks and 5 health systems. Big step for AI

Very exciting work demonstrating the emergence of in-context learning in Evo 2 on purely synthetic tasks.

Could clesrovimab, a human RSV monoclonal antibody, reduce the incidence of RSV infection in preterm and full-term infants? Find out in the latest video in our partnership with Dr. Glaucomflecken. Read the full results of the CLEVER trial for free: nej.md/DrG30

47% of Americans worry they can’t afford healthcare We don’t have to accept this. AI gives us a path to high-quality, low-cost care for all. Let’s make it real.

Today in nature we report a new prime editing strategy that can rescue a common cause of many genetic diseases in a disease-agnostic manner. This approach converts a redundant endogenous tRNA into an optimized suppressor tRNA, enabling a single prime edit to rescue premature

FDA Approves Selumetinib for Adult NF1 With Plexiform Neurofibromas targetedonc.com/view/fda-appro… #oncology #FDAapproved

A compound that enhances homology-directed repair in CRISPR editing leads to genome instability go.nature.com/3D2e4Fh rdcu.be/eQpUd

FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer | FDA ⁦OncoAlert⁩ ⁦GUARD Consortium⁩ ⁦ESMO - Eur. Oncology⁩ fda.gov/drugs/resource…

With proprietary (Chai-2, JAM-2) and open-source (BoltzGen, Germinal, MBER, Protein Hunter) antibody design platforms emerging, the real question is what this actually means for drug development going forward. As I wrote in June, AI is for the underdogs! ariax.bio/resources/ai-d…

A new JAMA analysis finds that 5% of the population carries pathogenic germline variants across key cancer-susceptibility genes far higher than expected. 🔗 doi:10.1001/jama.2025.16372 My take: This is exactly why we need AI-powered, population-level genomics. AI can help flag

Computing breakthrough Scientists have created a magnetic material with spins that twist in an ultra tiny helix, and it produces an electrical response far stronger than expected. Because it’s so easy to control and so powerful at this scale, it could open the door to

Durvalumab (+FLOT) is now U.S. FDA ✅ for resectable Gastric & GEJ adenocarcinoma based off #MATTERHORN! We 🗣️ this trial, findings, PDL1, and AEs w/ Yelena Y. Janjigian MD Full 🗣️: ⭐️ oncbrothers.com/fda-matterhorn… ⭐️ Also on “Oncology Brothers” podcast OncoAlert OncUpdates #gism

Great news for women Cervical Cancer May Be Treatable with Intranasal Nanogel Vaccine Scientists in Japan have created a breakthrough intranasal nanogel vaccine that could treat cervical cancer. Instead of a shot, it’s a gentle nasal spray that delivers HPV cancer triggering